Cargando…

The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder

OBJECTIVE: To assess the relative severity of nausea in patients from Korea with major depressive disorder (MDD) who were treated with duloxetine at low (30 mg) or high (60 mg) doses, with or without food, for the first week of an 8 week treatment. METHODS: Adult patients (n=249), with MDD and a 17-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Min-Soo, Ahn, Yong Min, Chung, Seockhoon, Walton, Richard, Raskin, Joel, Kim, Mun Sung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neuropsychiatric Association 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521117/ https://www.ncbi.nlm.nih.gov/pubmed/23251205 http://dx.doi.org/10.4306/pi.2012.9.4.391

Ejemplares similares

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
por: Mallinckrodt, Craig H, et al.
Publicado: (2005)

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)

Duloxetine-Induced Liver Injury in Patients with Major Depressive Disorder
por: Kang, Seung-Gul, et al.
Publicado: (2011)

Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
por: Park, Young-Min, et al.
Publicado: (2010)

Attributes of response in depressed patients switched to treatment with duloxetine
por: Sagman, D, et al.
Publicado: (2011)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada, Eiji, et al.
Publicado: (2016)

Duloxetine in the treatment of major depressive disorder: an open-label study
por: Hudson, James I, et al.
Publicado: (2007)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
por: Norman, Trevor R, et al.
Publicado: (2010)

The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity
por: Wise, T N, et al.
Publicado: (2007)

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
por: Ye, Wenyu, et al.
Publicado: (2011)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
por: Muscatello, Maria Rosaria Anna, et al.
Publicado: (2019)

Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
por: Fu, Cynthia HY, et al.
Publicado: (2015)

Duloxetine-Induced Hyponatremia in an Elderly Male Patient with Treatment-Refractory Major Depressive Disorder
por: Sun, Ching-Fang, et al.
Publicado: (2019)

Association between Painful Physical Symptoms and Clinical Outcomes in Korean Patients with Major Depressive Disorder: A Three-Month Observational Study
por: Lee, Min Soo, et al.
Publicado: (2009)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Depression Treatment with Duloxetine and Reduction of Inability to Work
por: Happich, Michael, et al.
Publicado: (2012)

A Korean Predictive Model for Postoperative Nausea and Vomiting
por: Choi, Duck Hwan, et al.
Publicado: (2005)

The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials
por: Mallinckrodt, Craig H, et al.
Publicado: (2004)

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
por: Polychroniou, Philip E., et al.
Publicado: (2018)

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick, Diego, et al.
Publicado: (2016)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
por: Haider, Miqdad, et al.
Publicado: (2017)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
por: Harada, Eiji, et al.
Publicado: (2015)

An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects
por: Fornaro, Michele, et al.
Publicado: (2011)

Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
por: Wohlreich, Madelaine M, et al.
Publicado: (2004)

Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study
por: Maund, Emma, et al.
Publicado: (2014)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
por: Ball, Susan G, et al.
Publicado: (2013)

Development of a Korean Version of the Perceived Deficits Questionnaire-Depression for Patients with Major Depressive Disorder
por: Kim, Jae-Min, et al.
Publicado: (2016)

Overactive Bladder Successfully Treated with Duloxetine in a Female Adolescent
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Duloxetine hydrochloride
por: Bhadbhade, Mohan, et al.
Publicado: (2009)

Duloxetine induced hyponatremia
por: Kulkarni, M.
Publicado: (2015)

Acute Dystonia after Using Single Dose Duloxetine: Case Report
por: Karakaş Uğurlu, Görkem, et al.
Publicado: (2013)

Study of Sex Differences in Duloxetine Efficacy for Depression in Transgenic Mouse Models
por: Xu, Yong, et al.
Publicado: (2017)

Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications
por: Maund, Emma, et al.
Publicado: (2014)

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression
por: Maciaszek, Julian, et al.
Publicado: (2023)

Use of select medications prior to duloxetine initiation among commercially-insured patients
por: Bernauer, Mark, et al.
Publicado: (2012)

CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression
por: Han, Kyu-Man, et al.
Publicado: (2013)

The Effect of Food on the Single‐Dose Bioavailability and Tolerability of the Highest Marketed Strength of Duloxetine
por: Rizea‐Savu, Simona, et al.
Publicado: (2019)

Does Duloxetine Improve Cognitive Function Independently of Its Antidepressant Effect in Patients with Major Depressive Disorder and Subjective Reports of Cognitive Dysfunction?
por: Greer, Tracy L., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_le7ca5v2took82ank832evkjje